CP-547632 NEW
| Price | $30 | $68 | $98 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-22 |
Product Details
| Product Name: CP-547632 | CAS No.: 252003-65-9 |
| Purity: 99.39% | Supply Ability: 10g |
| Release date: 2026/04/22 |
Product Introduction
Bioactivity
| Name | CP-547632 |
| Description | CP-547632 is an orally available and potent, ATP-competitive dual inhibitor of VEGFR-2 and FGF kinase F with IC50s of 11 nM and 9 nM, respectively. CP-547632 is selective, with higher selectivity for VEGFR2 and bFGF than for EGFR, PDGFRβ and related tyrosine kinases (TKs). PDGFRβ and related tyrosine kinases (TKs) CP-547632 has antitumour activity. |
| In vitro | CP-547632 (1-1000 nM ; 1 h) suppresses VEGF-induced VEGFR-2 phosphorylation in a concentration-dependent manner (IC50: 6 nM). [1] |
| In vivo | CP-547632 (oral ; 50 mg/kg) yieldes plasma concentrations above 500 ng/ml for 12 hours. CP-547632 (p.o. ; 6.25-100 mg/kg/day ; for 10-24 days) causes a dose-dependent inhibition of growth in Colo-205, DLD-1, and MDA-MB-231 xenografts.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 90 mg/mL (169.05 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (7.51 mM), Sonication is recommended. |
| Keywords | VEGFR-2 | VEGFR2 | PDGFRβ | FGFR | CP-547632 | CP547632 | CP 547632 | BTK | bFGFR |
| Inhibitors Related | Ribociclib | Amlexanox | Sorafenib | Ferulic Acid | Ibrutinib | glycine | Nintedanib esylate | Regorafenib | Chloramphenicol | Formononetin | Lenvatinib | Pazopanib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Angiogenesis related Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3400.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $44.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-07-17 | |
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 | ||
| $30.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-22 | |
| $1.00 |
VIP7Y
|
Career Henan Chemical Co
|
2020-01-13 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY